Cyclandelate in the Treatment of Patients with Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Vascular Dementia: Experience from a Placebo Controlled Multi-center Study
| Autor: | W. Wierich, G. Weyer, A. Eul, W. M. Herrmann, K. Milde |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty Vasodilator Agents Cyclandelate Placebo law.invention Placebos Double-Blind Method Randomized controlled trial Alzheimer Disease law Statistical significance Internal medicine mental disorders Humans Medicine Dementia Pharmacology (medical) Adverse effect Vascular dementia Aged Aged 80 and over business.industry Dementia Vascular General Medicine Middle Aged medicine.disease Surgery Clinical trial Psychiatry and Mental health Female business human activities medicine.drug |
| Zdroj: | Pharmacopsychiatry. 33:89-97 |
| ISSN: | 1439-0795 0176-3679 |
| Popis: | A 24-week, double-blind, multi-center, randomised parallel group study compared the efficacy and safety of 800 mg bid cyclandelate with placebo in patients with mild to moderate dementia of primary degenerative or vascular origin. A total of 196 patients entered the study, 147 patients completed treatment in adherence with the protocol. Primary outcome measures were the cognitive score of the Alzheimer's Disease Assessment Scale (ADAS-Cog), the subscale Instrumental Activities of Daily Living of the Nurses' Observation Scale for Geriatric Patients (NOSGER-IADL) and the Clinical Global Impressions of Change (CGI-C). Safety assessments included adverse events, vital signs, ECG and clinical laboratory parameters. The primary efficacy results based on a multi-level responder analysis including ADAS-Cog, NOSGER-IADL and CGI-C failed to demonstrate statistical superiority of cyclandelate in comparison to placebo. The direction of changes favored cyclandelate in each of the variables, but the differences to placebo were small and varied considerably between patients and centers. Retrospective exploratory analyses suggested that efficacy of cyclandelate might be dependent on the severity of the disease. The treatment effects in favor of cyclandelate were statistically significant in the subgroup of moderately impaired patients (MMSE at baseline18) for ADAS-Cog (delta = -4.0 points, p = 0.015) and CGI-C (delta = -0.4 points, p = 0.043) but not for NOSGER-IADL (delta = -1.6 points, p = 0.059). When patients were stepwise selected for the severity of the disease according to ADAS-Cog at baseline (15,20,25 points), statistical significance was reached for ADAS-Cog and NOSGER-IADL beginning with the step ADAS-Cog20 points: delta ADAS-Cog = -3.9 points, p = 0.044; delta NOSGER-IADL = -1.0, p = 0.023. The treatment differences increased further with the step ADAS-Cog25 points: delta ADAS-Cog = -7.0 points, p = 0.008; delta NOSGER-IADL = -1.7, p = 0.003. Treatment differences in CGI-C increased marginally with the stepwise selection but did not reach statistical significance. The drug was safe and well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|